Search Results - "MYERS, W L"

Refine Results
  1. 1
  2. 2

    A Health-Related Quality of Life Measure for Multiple Sclerosis by Vickrey, B G, Hays, R D, Harooni, R, Myers, L W, Ellison, G W

    Published in Quality of life research (01-06-1995)
    “…The need for measures of health-related quality of life (HRQOL) for clinical effectiveness research and for quality of care research, particularly for chronic…”
    Get full text
    Journal Article
  3. 3

    The Mayflies (Ephemeroptera), Stoneflies (Plecoptera), and Caddisflies (Trichoptera) of the Adirondack Park (New York State) by Myers, L. W, Kondratieff, B. C, Mihuc, T. B, Ruiter, D. E

    “…James Needham and Cornelius Betten in 1901 published one the first studies of aquatic insects in North America providing life history information for a number…”
    Get full text
    Journal Article
  4. 4

    Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial by Johnson, K P, Brooks, B R, Ford, C C, Goodman, A D, Lisak, R P, Myers, L W, Pruitt, A A, Rizzo, M A, Rose, J W, Weiner, L P, Wolinsky, J S

    Published in Multiple sclerosis (01-12-2003)
    “…The aim of this study was to assess the long-term safety and efficacy of glatiramer acetate (GA) for patients with multiple sclerosis (MS) who received active…”
    Get full text
    Journal Article
  5. 5

    Spatially constrained clustering and upper level set scan hotspot detection in surveillance geoinformatics by Patil, G. P, Modarres, R, Myers, W. L, Patankar, P

    Published in Environmental and ecological statistics (01-12-2006)
    “…We discuss upper level set (ULS) scan as a type of spatially constrained clustering in relation to two ways of imposing the spatial constraint, retrospectively…”
    Get full text
    Journal Article
  6. 6

    Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years by Johnson, K P, Brooks, B R, Ford, C C, Goodman, A, Guarnaccia, J, Lisak, R P, Myers, L W, Panitch, H S, Pruitt, A, Rose, J W, Kachuck, N, Wolinsky, J S

    Published in Multiple sclerosis (01-08-2000)
    “…In a randomized, placebo-controlled, double-blind study, glatiramer acetate (Copaxone®) reduced the relapse rate and slowed accumulation of disability for…”
    Get full text
    Journal Article
  7. 7

    A humoral response to oligodendrocyte-specific protein in MS: A potential molecular mimic by BRONSTEIN, J. M, LALLONE, R. L, SEITZ, R. S, ELLISON, G. W, MYERS, L. W

    Published in Neurology (13-07-1999)
    “…To determine the antibody response to oligodendrocyte-specific protein (OSP) in patients with MS. OSP is a recently identified CNS-specific myelin protein that…”
    Get full text
    Journal Article
  8. 8

    Management of multiple sclerosis across managed care and fee-for-service systems by VICKREY, B. G, SHATIN, D, ELLISON, G. W, WOLF, S. M, MYERS, L. W, BELIN, T. R, HANSON, R. A, SHAPIRO, M. F, BECKSTRAND, M, EDMONDS, Z. V, DELRAHIM, S

    Published in Neurology (14-11-2000)
    “…To measure and compare care for adults with MS across managed care and fee-for-service (FFS) health systems. The authors sampled adults with MS having…”
    Get full text
    Journal Article
  9. 9

    Comparison of a generic to disease-targeted health-related quality-of-life measures for multiple sclerosis by Vickrey, Barbara G., Hays, Ron D., Genovese, Barbara J., Myers, Lawrence W., Ellison, George W.

    Published in Journal of clinical epidemiology (01-05-1997)
    “…Evaluation of the relative contributions of generic and disease-targeted measures to assessing health-related quality of life (HRQOL) for chronic conditions is…”
    Get full text
    Journal Article
  10. 10

    General neurologist and subspecialist care for multiple sclerosis : Patients' perceptions by VICKREY, B. G, EDMONDS, Z. V, SHATIN, D, SHAPIRO, M. F, DELRAHIM, S, BELIN, T. R, ELLISON, G. W, MYERS, L. W

    Published in Neurology (12-10-1999)
    “…To compare general neurologists and MS specialists on patients' clinical characteristics and MS care as perceived by patients with MS. We sampled all adult…”
    Get full text
    Journal Article
  11. 11

    Neutron detectors for active interrogation of highly enriched uranium by Moss, C.E., Goulding, C.A., Hollas, C.L., Myers, W.L.

    Published in IEEE transactions on nuclear science (01-08-2004)
    “…We describe the results of our effort to optimize three neutron detector systems for active interrogation of highly enriched uranium: 1) a large-area detector…”
    Get full text
    Journal Article
  12. 12

    Factors related to agreement between self-reported and conventional Expanded Disability Status Scale (EDSS) scores by Cheng, E.M., Hays, R.D., Myers, L.W., Ellison, G.W., Beckstrand, M., Vickrey, B.G.

    Published in Multiple sclerosis (01-12-2001)
    “…Although the Expanded Disability Status Scale (EDSS) remains a widely used scale for evaluating impairments in people with multiple sclerosis (MS), EDSS…”
    Get full text
    Journal Article
  13. 13

    T-cell responses to oligodendrocyte-specific protein in multiple sclerosis by Vu, T., Myers, L.W., Ellison, G.W., Mendoza, F., Bronstein, J.M.

    Published in Journal of neuroscience research (01-11-2001)
    “…Oligodendrocyte‐specific protein (OSP) is concentrated in CNS myelin and is a potential autoantigen in the development of multiple sclerosis (MS). We performed…”
    Get full text
    Journal Article
  14. 14

    Cerebrospinal fluid immunoglobulin G promotes oligodendrocyte progenitor cell migration by Tiwari-Woodruff, S.K., Myers, L.W., Bronstein, J.M.

    Published in Journal of neuroscience research (01-08-2004)
    “…Multiple sclerosis (MS) is characterized by demyelination of the CNS with associated neurological deficits. Remyelination can occur but is often incomplete…”
    Get full text
    Journal Article
  15. 15

    Pentoxifylline is not a promising treatment for multiple sclerosis in progression phase by MYERS, L. W, ELLISON, G. W, DAVIS, P, GRANGER, D, FAHEY, J. L, MERRILL, J. E, EL HAJJAR, A, PIERRE, B. S, HIJAZIN, M, LEAKE, B. D, BENTSON, J. R, NUWER, M. R, TOURTELLOTTE, W. W

    Published in Neurology (01-11-1998)
    “…Fourteen MS patients took pentoxifylline at varying doses for up to 24 months. In vitro production of tumor necrosis factor alpha was reduced in patients…”
    Get full text
    Journal Article
  16. 16

    Multiscale advanced raster map analysis system: Definition, design and development by Patil, G, Balbus, J, Biging, G, JaJa, J, Myers, W L, Taillie, C

    Published in Environmental and ecological statistics (01-06-2004)
    “…This paper brings together a multidisciplinary initiative to develop advanced statistical and computational techniques for analyzing, assessing, and extracting…”
    Get full text
    Journal Article
  17. 17

    Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years by Johnson, K.P., Brooks, B.R., Ford, C.C., Goodman, A., Guarnaccia, J., Lisak, R.P., Myers, L.W., Panitch, H.S., Pruitt, A., Rose, J.W., Kachuck, N., Wolinsky, J.S.

    Published in Multiple sclerosis (01-04-2000)
    “…In a randomized, placebo-controlled, double-blind study, glatiramer acetate (Copaxone) reduced the relapse rate and slowed accumulation of disability for…”
    Get full text
    Journal Article
  18. 18

    Use of a COTS X-ray scanner for 2-D neutron activation analysis by Bounds, J. A., Goda, J. M., Myers, W. L., Rose, E. A., Sanchez, R. G.

    “…Results from the use of a commercial, off-the-shelf X-ray scanner using storage phosphors to measure neutron activation in 1- and 2-D are presented. The…”
    Get full text
    Journal Article
  19. 19

    Detection and delineation of critical areas using echelons and spatial scan statistics with synoptic cellular data by Patil, G. P., Bishop, J. A., Myers, W. L., Taillie, C., Vraney, R., Wardrop, Denice

    Published in Environmental and ecological statistics (01-06-2004)
    “…Geographical surveillance for hotspot detection and delineation has become an important area of investigation both in geospatial ecosystem health and in…”
    Get full text
    Journal Article
  20. 20

    A placebo-controlled, randomized, double-masked, variable dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis by ELLISON, G. W, MYERS, L. W, MICKEY, M. R, GRAVES, M. C, TOURTELLOTTE, W. W, SYNDULKO, K, HOLEVOET-HOWSON, M. I, LERNER, C. D, FRANE, M. V, PETTLER-JENNINGS, P

    Published in Neurology (01-08-1989)
    “…Ninety-eight patients with multiple sclerosis (MS) in the chronic progression phase entered a 3-year clinical trial to determine if azathioprine (AZ) alone or…”
    Get full text
    Journal Article